Importantly, the serum toxicity of the patient with recurrent FSGS who favorably responded to TNFα blockade in vivo (previously described by our group in [22]) could be strongly suppressed by TNFα blockade in our FAC assay (S2A Fig). The gene discussed is TNF; the disease is focal segmental glomerulosclerosis.